

[FDA Issues Artificial Intelligence/Machine Learning \(AI/ML\)-Enabled Device Software Functions Draft Guidance](#)



The U.S. Food and Drug Administration recently issued its [draft guidance](#) entitled “Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions.” The draft guidance follows the passage of the Food and Drug Omnibus Reform Act of 2022 (FDORA), which explicitly authorized the Agency to approve or clear Predetermined Change Control Plans (PCCPs).

We summarize some of the key takeaways from FDA’s draft guidance. Read the client alert [here](#).